Aurobindo Pharma Limited share price
NSE: AUROPHARMA · ISIN INE406A01037
Key numbers
- Market cap
- ₹ 98,505 Cr
- Current price
- ₹ 1,712.00
- 52-week high / low
- ₹ 1,740 / 1,067
- Stock P/E
- 26.7
- Book value
- ₹ 652.4
- Dividend yield
- 0.23%
- ROCE
- 12.6%
- ROE
- 9.9%
- Debt to equity
- 0.21
- Sales growth (3 yrs)
- 10.7%
- Profit growth (3 yrs)
- 22.1%
- 1-year return
- 54.2%
About Aurobindo Pharma Limited
Aurobindo Pharma Limited, a pharmaceutical company, develops, manufactures, and commercializes generic pharmaceuticals in India, the United States, Europe, and internationally. The company manufactures a range of finished formulation products in various forms, such as oral solids, liquids, injectables for generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingredients for CNS, anti-retroviral, cardiovascular, antibiotics, gastroenterology, anti-diabetics, and anti-allergic therapeutic areas. It also provides ointments, creams, gels, powders, transdermal, and lotions; antiretroviral drugs for PLHIV & CLHIV; and injectable products, including Penems, Penicillin, Cephalosporin, ophthalmic, inhalation, oncology, and hormone products. The company was incorporated in 1986 and is headquartered in Hyderabad, India.
Quarterly results
Consolidated figures in ₹ crores
| Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 8,381 | 7,792 | 8,605 | 8,752 | 9,106 |
| Operating profit | 1,792 | 1,603 | 1,773 | 1,801 | 1,881 |
| Net profit | 903 | 825 | 910 | 921 | 1,033 |
| EPS (₹) | 15.56 | 14.20 | 15.67 | 15.86 | 17.86 |
Concall summary (2026-08-13)
AI summary of the earnings call transcript · tone: Positive · source document
Guidance & outlook
- Aurobindo Pharma Limited 06 August 2026 Gross margin remained resilient at 60.4% compared to 58.8% of Q1 FY26, benefiting from an improved business mix and operating efficiency.
- However, we expect the tax rate to normalise around 28 -29% by year-end.
Growth & demand
- 9,150 crores driven by broad-based performance across our business area. • European growth market maintained strong momentum and our U.S. business contained a sustained growth. • Operating EBITDA, exploring one -time impact of Rs.
Margins & costs
- Our average finance cost declined to 4.8% from 5% in the previous quarter, reflecting prudent treasury management.
- So the margin front from China, last year we had a loss of around 7 million EBITDA.
Capex & expansion
- So, the China plant, we are having a capacity of more than 2 billion tablets.
- If this becomes mandatory for us to do it, I believe that if somebody is prepared to handle it, Aurobindo is the one, because we already have a manufacturing facility in the form of Lannett, and that we can manufacture up to 350 million at ease, without too much of CAPEX.
Balance sheet & cash
- 1,032 crores, reflecting a healthy operating leverage and efficient capital management.
- We believe Aurobindo is steadily transforming into a more differentiated pharmaceutical company with multiple levers, higher quality earnings and stronger free cash flows and sustained ROCE.
Peers in Drug Manufacturers - Specialty & Generic
Data for information only, not investment advice. Prices end of day.